Acute Promyelocytic Leukemia with Trisomy 8 and Del(9)(q22) after Treatment of Cervical Cancer with Concurrent Chemoradiotherapy: A Case Report

Juwon Kim,Tae Sung Park,Jin Seok Kim,Jaewoo Song,Kyung-A Lee,Sun Young Cho,Seung Hwan Oh,Jong Rak Choi

DOI: https://doi.org/10.1159/000329612

2011-01-01

Oncology Research and Treatment

Abstract:fever. The complete blood count (CBC) showed a hemoglobin level of 6.8 g/dl, a white blood cell count of 4.0 10/l with > 5% hypersegmented neutrophils and promyelocytes, and platelet counts of 28 10/l. Coagulation tests revealed a prothrombin time of 14.8 s (reference range 9.8–13.4 s), an activated partial thromboplastin time of 36.2 s (reference range 27.9–41.6 s), a fibrinogen level of 104 mg/dl (reference range 200–400 mg/dl), fibrin degradation product levels of 100 μg/dl (reference range < 5 μg/dl) and a D-dimer level of 2,909 ng/ml (reference range 0–243 ng/ml). Bone marrow aspiration showed a hypocellular marrow with 76% blasts and promelocytes with heavy azurophilic granulation and polymorphic nuclei. Bone marrow biopsy revealed less than 10% cellularity with interstitially scattered immature myeloid cells having eccentric nuclei, consistent with APL. Immunophenotyping demonstrated 82.4% CD13-positive cells and 70.7% CD33-positive cells, which were, however, negative for CD34 and HLA-DR. The karyotype showed 47,XX,+8,del(9)(q22),t(15;17)(q22;q12) in 20 metaphase cells out of 26 counted (fig. 1). Fluorescence in situ hybridization (FISH) signals from PML/RAR (promyelocytic leukemia gene/retinoic acid receptor gene) showed the result of ‘nuc ish (PML, RAR )X3(PML con RAR X2) [55/300]’, consistent with the abnormal pattern of 1O1G2Y in 18.3% of the nuclei examined. The diagnosis of APL accompanying disseminated intravascular coagulation (DIC) was made. The first induction chemotherapy (modified anthracyclin-based chemotherapy (AIDA)) was given with vesanoid (45 mg/m) followed by idarubicin therapy (12 mg/m, on days 2, 4, 6 and 8) and molecular complete remission (CR) was achieved. The first consolidation therapy with mitoxantrone and the second consolidation with idarubicin were carried out. The patient is on maintenance therapy with 6-mercaptopurine and methotrexate, with close follow-up.